Related Experiment Video

Updated: Aug 15, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

[The binding capacity of albumin in patients with gastric cancer]

A N Afanas'eva, V A Evtushenko

    Klinicheskaia Laboratornaia Diagnostika
    |August 5, 2005
    PubMed

    More Related Videos

    Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer07:50

    Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

    Published on: September 18, 2020

    Laparoscopic Radical Gastrectomy for Remnant Gastric Cancer05:30

    Laparoscopic Radical Gastrectomy for Remnant Gastric Cancer

    Published on: October 31, 2025

    Related Concept Videos

    Drug Distribution: Tissue Binding01:21

    Drug Distribution: Tissue Binding

    Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
    For...
    Drug Distribution: Plasma Protein Binding01:29

    Drug Distribution: Plasma Protein Binding

    Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
    Drug Binding to Blood Components01:30

    Drug Binding to Blood Components

    When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
    HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
    Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

    Factors Affecting Protein-Drug Binding: Patient-Related Factors

    Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
    Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
    Hepatic Drug Clearance: Effect of Protein Binding01:09

    Hepatic Drug Clearance: Effect of Protein Binding

    Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
    For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

    Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...